David Farley

1.7k total citations
17 papers, 970 citations indexed

About

David Farley is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, David Farley has authored 17 papers receiving a total of 970 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 7 papers in Cancer Research and 4 papers in Oncology. Recurrent topics in David Farley's work include Protease and Inhibitor Mechanisms (7 papers), Cell Adhesion Molecules Research (4 papers) and Enzyme Production and Characterization (2 papers). David Farley is often cited by papers focused on Protease and Inhibitor Mechanisms (7 papers), Cell Adhesion Molecules Research (4 papers) and Enzyme Production and Characterization (2 papers). David Farley collaborates with scholars based in United States, Switzerland and United Kingdom. David Farley's co-authors include James Travis, Jan Potempa, Walker T. McGraw, Guy S. Salvesen, Jon D. Shuman, Alan Przybyla, Christopher Reilly, Kristen Johnson, Robert Terkeltaub and Shou‐Ih Hu and has published in prestigious journals such as Nucleic Acids Research, Biochemistry and Journal of Medicinal Chemistry.

In The Last Decade

David Farley

17 papers receiving 951 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Farley United States 12 383 286 180 155 149 17 970
Stephen Demczuk Switzerland 9 409 1.1× 233 0.8× 23 0.1× 180 1.2× 393 2.6× 16 1.2k
K Fehr Switzerland 20 298 0.8× 546 1.9× 25 0.1× 191 1.2× 472 3.2× 60 1.4k
Koji Suda Japan 12 794 2.1× 129 0.5× 99 0.6× 223 1.4× 558 3.7× 20 1.3k
Sabine Krueger Germany 21 407 1.1× 156 0.5× 19 0.1× 303 2.0× 183 1.2× 35 1.1k
A M Pitts United States 13 181 0.5× 107 0.4× 26 0.1× 42 0.3× 302 2.0× 25 694
M. Leverkus Germany 19 832 2.2× 120 0.4× 22 0.1× 241 1.6× 458 3.1× 28 1.4k
Hans-Jürgen Gober China 12 407 1.1× 118 0.4× 27 0.1× 119 0.8× 793 5.3× 22 1.4k
Tetsuhiko Asao Japan 18 309 0.8× 24 0.1× 92 0.5× 160 1.0× 124 0.8× 66 932
Heinz‐Joachim Radzun Germany 15 488 1.3× 25 0.1× 48 0.3× 137 0.9× 289 1.9× 38 1.0k
M Feldmann United Kingdom 11 216 0.6× 653 2.3× 13 0.1× 94 0.6× 512 3.4× 18 1.3k

Countries citing papers authored by David Farley

Since Specialization
Citations

This map shows the geographic impact of David Farley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Farley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Farley more than expected).

Fields of papers citing papers by David Farley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Farley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Farley. The network helps show where David Farley may publish in the future.

Co-authorship network of co-authors of David Farley

This figure shows the co-authorship network connecting the top 25 collaborators of David Farley. A scholar is included among the top collaborators of David Farley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Farley. David Farley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Farley, David, et al.. (2025). Risks of replication-competent retro/lentivirus from associated vector systems: Is it time for a roadmap toward reduced testing?. Molecular Therapy — Methods & Clinical Development. 33(4). 101601–101601. 1 indexed citations
2.
Wright, J. Fraser, et al.. (2024). THE TETRAVECTA™ SYSTEM: A NEW TOOL KIT ENHANCING LENTIVIRAL VECTOR PRODUCTION FOR THE NEXT GENERATION OF GENE THERAPIES. Cytotherapy. 26(6). S208–S208. 1 indexed citations
3.
Griner, Lesley A. Mathews, Huyen Thi Lam Nguyen, David Farley, et al.. (2018). Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening. Journal of Visualized Experiments. 9 indexed citations
4.
Peppard, Jane, Quynhchi Pham, David Farley, et al.. (2003). Development of an Assay Suitable for High-Throughput Screening to Measure Matrix Metalloprotease Activity. Assay and Drug Development Technologies. 1(3). 425–433. 11 indexed citations
5.
Greenspan, Paul D., Kirk Clark, Scott D. Cowen, et al.. (2003). N-Arylaminonitriles as bioavailable peptidomimetic inhibitors of cathepsin B. Bioorganic & Medicinal Chemistry Letters. 13(22). 4121–4124. 22 indexed citations
6.
Johnson, Kristen, David Farley, Shou‐Ih Hu, & Robert Terkeltaub. (2003). One of two chondrocyte‐expressed isoforms of cartilage intermediate‐layer protein functions as an insulin‐like growth factor 1 antagonist. Arthritis & Rheumatism. 48(5). 1302–1314. 53 indexed citations
7.
Johnson, Kristen, James W. Goding, Deborah Van Etten, et al.. (2003). Linked Deficiencies in Extracellular PPi and Osteopontin Mediate Pathologic Calcification Associated With Defective PC-1 and ANK Expression. Journal of Bone and Mineral Research. 18(6). 994–1004. 164 indexed citations
8.
Altmann, Eva, Johanne Renaud, Jonathan A. Green, et al.. (2002). Arylaminoethyl Amides as Novel Non-Covalent Cathepsin K Inhibitors. Journal of Medicinal Chemistry. 45(12). 2352–2354. 36 indexed citations
9.
McGraw, Walker T., Jan Potempa, David Farley, & James Travis. (1999). Purification, Characterization, and Sequence Analysis of a Potential Virulence Factor from Porphyromonas gingivalis , Peptidylarginine Deiminase. Infection and Immunity. 67(7). 3248–3256. 302 indexed citations
10.
Farley, David, et al.. (1993). Cloning and sequence analysis of rat hepsin, a cell surface serine proteinase. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1173(3). 350–352. 9 indexed citations
11.
Faller, Bernard, David Farley, & Hanspeter Nick. (1993). Finasteride: A slow-binding 5.alpha.-reductase inhibitor. Biochemistry. 32(21). 5705–5710. 68 indexed citations
12.
Farley, David, et al.. (1991). Expression of rat 5α-reductase in Saccharomyces cerevisiae. The Journal of Steroid Biochemistry and Molecular Biology. 39(4). 487–492. 9 indexed citations
13.
Farley, David, James Travis, & Guy S. Salvesen. (1989). The Human Neutrophil Elastase Gene. Analysis of the Nucleotide Sequence Reveals Three Distinct Classes of Repetitive DNA. Biological Chemistry Hoppe-Seyler. 370(2). 737–744. 12 indexed citations
14.
Wątorek, Wiesław, David Farley, Guy S. Salvesen, & James C. Travis. (1988). Neutrophil Elastase and Cathepsin G: Structure, Function, and Biological Control. Advances in experimental medicine and biology. 240. 23–31. 36 indexed citations
15.
Farley, David, et al.. (1988). Molecular cloning of human neutrophil elastase.. PubMed. 369 Suppl. 3–7. 13 indexed citations
16.
Salvesen, Guy S., David Farley, Jon D. Shuman, et al.. (1987). Molecular cloning of human cathepsin G: structural similarity to mast cell and cytotoxic T lymphocyte proteinases. Biochemistry. 26(8). 2289–2293. 187 indexed citations
17.
Salvesen, Guy S., et al.. (1987). cDNA encoding a human homolog of yeast ubiquitin 1. Nucleic Acids Research. 15(13). 5485–5485. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stephen Demczuk Breakdown of academic impact, for papers by K Fehr Breakdown of academic impact, for papers by Koji Suda Breakdown of academic impact, for papers by Sabine Krueger Breakdown of academic impact, for papers by A M Pitts Breakdown of academic impact, for papers by M. Leverkus Breakdown of academic impact, for papers by Hans-Jürgen Gober Breakdown of academic impact, for papers by Tetsuhiko Asao Breakdown of academic impact, for papers by Heinz‐Joachim Radzun Breakdown of academic impact, for papers by M Feldmann
Rankless by CCL
2026